María Gabriela Echeverría-Garcés

María Gabriela Echeverría-Garcés

Red Latinoamericana de Implementación y Validación de Guías Clínicas Farmacogenómicas, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in Biology
Verified
Journal Article
Open access
PDF file
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
MEMaría Gabriela Echeverría-Garcés
María Gabriela Echeverría-Garcés
MRMaria Jose Ramos
Maria Jose Ramos
The condition known as 5q spinal muscular atrophy (SMA) is a devastating autosomal recessive neuromuscular disease caused by a deficiency of the ubiquitous protein survival of motor neuron (SMN), which is encoded by the SMN1 and SMN2 genes. It is one of the most common pediatric recessive genetic diseases, and it represents the most common cause of hereditary infant mortality. After decades of intensive basic and clinical research efforts, and improvements in the standard of care, successful therapeutic milestones have been developed, delaying the progression of 5q SMA and increasing patient survival. At the same time, promising data from early-stage clinical trials have indicated that additional therapeutic options are likely to emerge in the near future. Here, we provide updated information on the molecular underpinnings of SMA; we also provide an overview of the rapidly evolving therapeutic landscape for SMA, including SMN-targeted therapies, SMN-independent therapies, and combinational therapies that are likely to be key for the development of treatments that are effective across a patient’s lifespan.

20 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
Andrés Carrazco-MontalvoAndrés Carrazco-Montalvo
Andrés Carrazco-Montalvo
LLLucia Luje
Lucia Luje
CRCristina Jeanneth Rodríguez-Pólit
Cristina Jeanneth Rodríguez-Pólit
AAAntonio Ampuño
Antonio Ampuño
LPLeandro Patiño
Leandro Patiño
DTDavid De la Torre
David De la Torre
Highly pathogenic avian influenza A(H5N1) virus clade 2.3.4.4b was detected in four wild birds of two species, Fregata magnificens and Sula nebouxii , on the Ecuadorian Coast. This report highlights the importance of intersectoral collaboration and timely genotyping for monitoring this zoonotic pathogen, especially in regions with a rich biodiversity.

28 May 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
Andrés Carrazco-MontalvoAndrés Carrazco-Montalvo
Andrés Carrazco-Montalvo
DGDiana Stefania Gutierrez
Diana Stefania Gutierrez
JGJOHANNA VALENTINA AREVALO GRANDA
JOHANNA VALENTINA AREVALO GRANDA
PPPatricio Ponce
Patricio Ponce
CRCristina Jeanneth Rodríguez-Pólit
Cristina Jeanneth Rodríguez-Pólit
VCVarsovia Enid Cevallos
Varsovia Enid Cevallos
Ecuador, a tropical country with frequent dengue outbreaks, including a surge from 16,017 cases in 2022 to 61,329 in 2024, was the focus of this study. The study was conducted in Borbon, a semi-urban rural town in the Esmeraldas province. Genomic analysis, alongside entomo-virological surveillance, provides valuable insights into DENV-2 genotypes. Five pools of female Aedes aegypti mosquitoes from Borbon tested positive for DENV serotype 2 through RT-qPCR. One positive pool (CT = 16.13) was sequenced using Illumina MiSeq, and genotyping was conducted via the Dengue Typing Tool and Maximum Likelihood phylogenetic tree. The genotype assigned was III Southern Asian-American. Comparison with other genomes revealed genetic similarity to a human dengue genome sequenced in 2021, also from Esmeraldas, clustering with genomes reported across the Americas, particularly from Colombia and Venezuela. This study enhances our understanding of dengue virus epidemiology in rural areas, emphasizing the critical role of clinical case surveillance and vector monitoring in guiding evidence-based interventions.

Verified
Journal Article
Open access
PDF file
MMMiguel Martinez-Fresneda Mestre
Miguel Martinez-Fresneda Mestre
ELEsteban Nicolás Lizano
Esteban Nicolás Lizano
MEMaría Gabriela Echeverría-Garcés
María Gabriela Echeverría-Garcés
AHAndrés Herrera-Yela
Andrés Herrera-Yela
DFDanna Feijóo
Danna Feijóo
JRJosé Rubén Ramírez-Iglesias
José Rubén Ramírez-Iglesias
Plasma membrane Ca2+-ATPases (PMCA) are activated by calmodulin (CaM) via a C-terminal calmodulin-binding domain, CaMBD. Although specific mutations in this domain have been linked to disease, the broader impact of alternative substitutions across the interface remains unexplored. We applied an integrative in silico workflow to test six substitutions within CaMBD positions 1–18, L5R, N6I, I8T, V14E/D, and F18S, across PMCA isoforms 1–4. CaMBD sequences were aligned across isoforms, and candidates for substitutions were selected by conservation and nucleotide feasibility, prioritizing conserved or co-evolutionarily relevant sites, with substitutions possible by single-nucleotide change. PolyPhen-2 screened the impact of the substitutions on the protein functionality, the DisGeNET database was used to contextualize ATP2B genes with clinical phenotypes, and structural models plus binding free energy changes were estimated with AlphaFold3, FoldX, and MutaBind2. Effects were isoform and subregion dependent, with the strongest weakening toward the CaMBD C-terminus. V14E/D and F18S showed the largest and consistent predicted destabilization, consistent with disruption of conserved hydrophobic anchors. I8T and L5R had mixed outcomes depending on isoform, while N6I presented various scenarios with no clear effect. PolyPhen-2 classified most tested substitutions as damaging. Gene-disease evidence linked ATP2B to neurological, endocrine, and oncologic phenotypes, consistent with roles in Ca2+ homeostasis. Overall, CaMBD appears highly sensitive to perturbation, with distal positions 14–18 particularly vulnerable to substitutions that can destabilize CaM binding and potentially impair PMCA-mediated Ca2+ clearance in susceptible tissues.

1 December 2017 in Forensic Science International: Genetics Supplement Series
Verified
Journal Article
Closed access
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
MEMaría Gabriela Echeverría-Garcés
María Gabriela Echeverría-Garcés
GBGermán Burgos
Germán Burgos
AZAna Karina Zambrano
Ana Karina Zambrano
Alejandro Cabrera-AndradeAlejandro Cabrera-Andrade
Alejandro Cabrera-Andrade
CPCesar Paz-y-Mino
Cesar Paz-y-Mino

17 August 2021 in Research Square
Verified
Preprint
Open access
PDF file
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
SGSantiago Guerrero
Santiago Guerrero
EOEsteban Ortiz-Prado
Esteban Ortiz-Prado
VYVeronica Yumiceba
Veronica Yumiceba
AVAntonella Vera-Gupi
Antonella Vera-Gupi
Nikolaos KyriakidisNikolaos Kyriakidis
Nikolaos Kyriakidis
There is pressing urgency to identify drugs that allow treating COVID-19 patients effectively. Respiratory failure is the leading cause of death in patients with severe COVID-19, and the host inflammatory response at the lungs remains poorly understood. Therefore, we retrieved data from postmortem lungs from COVID-19 patients and performed in-depth in silico analyses of single-nucleus RNA sequencing data, inflammatory protein interactome network, functional enrichment, and shortest pathways to cancer hallmark phenotypes to reveal potential therapeutic targets and drugs in advanced-stage COVID-19 clinical trials. Herein, we analyzed transcriptomics data of 719 inflammatory response genes across 19 cell types (116,313 nuclei) from lung autopsies. The functional enrichment analysis of the 233 significantly expressed genes showed that the most relevant biological annotations were: inflammatory response, innate immune response, cytokine production, interferon production, macrophage activation, thymic stromal lymphopoietin, blood coagulation, IL-1 and megakaryocytes in obesity, NLRP3 inflammasome complex, and the TLR, JAK-STAT, NF-κB, TNF, oncostatin M, AGE-RAGE signaling pathways. Subsequently, we identified 34 essential inflammatory proteins with both high-confidence protein interactions and shortest pathways to inflammation, cell death, glycolysis, and angiogenesis. Lastly, we propose five small molecules involved in advanced-stage COVID-19 clinical trials: baricitinib, pacritinib, and ruxolitinib are tyrosine-protein kinase JAK2 inhibitors, losmapimod is a MAP kinase p38 alpha inhibitor, and eritoran is a TLR4/MD-2 antagonist. After being thoroughly analyzed in COVID-19 clinical trials, these drugs can be considered for treating severe COVID-19 patients.